ClinicalTrials.gg

Program

NBP608

A development code. Also written as “NBP608 (Mid Potency)” and “NBP608 (Low Potency)”.

Its studies are mostly in Chickenpox · Herpes Zoster, led by SK Chemicals.

Furthest: phase 3, since Apr 11, 20175 company-led studies, 1 open or runningNext primary completion: Feb 13, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SK Chemicals51 open or runningphase 3since Apr 11, 2017Apr 11, 2017Feb 13, 2027phase 3 · NCT07415252

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 11, 2017First study: phase 2 study in ChickenpoxFirst studyNCT03114982 · 152 enrolled · Philippines
  2. Apr 11, 20173 phase 3 studiesNCT03114943, NCT03120364, NCT03116594
  3. Jan 27, 2026Phase 3 study in ChickenpoxNCT07415252 · 780 planned · Honduras, Philippines, South Korea and more

Ahead

  1. Feb 13, 2027Primary completion: phase 3 study in ChickenpoxNCT07415252

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07415252Chickenpox · Honduras, Philippines, South Korea and more3RecruitingFeb 13, 2027780
NCT03120364Herpes Zoster · Korea, Republic of3CompletedDec 16, 2015824
NCT03116594Herpes Zoster · Korea, Republic of3CompletedApr 8, 2014675
NCT03114982Chickenpox · Philippines2CompletedJul 2016152
NCT03114943Chickenpox · Philippines3CompletedJun 28, 2017516

How it is read

Names in the registry

  • “NBP608”, 4 entries
  • “NBP608 (Mid Potency)”, 1 entry
  • “NBP608 (Low Potency)”, 1 entry

Codes read as this program: NBP608.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
NBP608 (SK Chemicals): development program | ClinicalTrials.gg